← Back to Profile Company Fact Sheet

Human Metabolome Technologies, Inc.

6090 ヒューマン・メタボローム・テクノロジーズ株式会社
Services · Standard · TSE: Disclosed
PRICE: ¥610 · MKT CAP: ¥3.5B · P/E: 14.0x · P/B: 1.84x · DIV YIELD: 2.5%
PRICE — 5Y
Characteristics & Business Summary
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays...
Income Statement Highlights (¥ Million, except EPS/DPS in ¥)
Fiscal Period FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 Forecast
Net Sales 1,124 1,223 1,299 1,346 1,455 1,600
Operating Profit 39 191 211 220 250
Ordinary Profit 60 253 233 241 241 1,600
Net Profit 58 268 286 243 256 1
EPS ¥10 ¥45 ¥48 ¥41 ¥45 ¥0
DPS ¥0 ¥0 ¥10 ¥15 ¥15
Balance Sheet & Valuation Highlights
Total Assets
Net Assets (Equity)
Equity Ratio
ROE (Return on Equity)
Cash & Equivalents
Interest-Bearing Debt
Capital Expenditure (CapEx)
Depreciation & Amort.
Major Shareholders
  • 1. 冨田 勝 6.9%
  • 2. M3, Inc. 3.8%
  • 3. 曽我 朋義 3.6%
  • 4. Dai-ichi Life Insurance 3.3%
  • 5. 西岡 孝明 2.6%
  • 6. The Yamagata Bank, Ltd. 2.6%
  • 7. 株式会社平田牧場 2.6%
  • 8. 株式会社荘内銀行 2.6%
  • 9. 楢崎 勝己 1.8%
  • 10. 冨田 勝 6.6%
Activist Activity
No large shareholder activist campaigns detected.
Historical Per-Share Data & Valuation Ratios
Per Share Metric FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 Forecast
Revenues per share ¥191 ¥207 ¥220 ¥227 ¥256 ¥281
FCF/Share ¥-10 ¥31 ¥32 ¥35 ¥39
EPS ¥10 ¥45 ¥48 ¥41 ¥45 ¥0
DPS ¥0 ¥0 ¥10 ¥15 ¥15
Capital Spending per share ¥5 ¥24 ¥17 ¥5 ¥26 ¥0
Book Value per share ¥197 ¥242 ¥291 ¥323 ¥336
Common Shares Outstanding 6M 6M 6M 6M 6M
Financial Aggregates & Margins
Financial Aggregate FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 Forecast
Revenues (Net Sales) ¥1B ¥1B ¥1B ¥1B ¥1B ¥2B
Operating Margin (%) 3.5% 15.6% 16.2% 16.4% 17.1%
Net Profit (owners) ¥0B ¥0B ¥0B ¥0B ¥0B ¥0B
Net Profit Margin (%) 5.2% 21.9% 22.0% 18.1% 17.6% 0.1%
Working Capital ¥1B ¥1B ¥1B ¥1B ¥1B
Total Debt (Interest-bearing) ¥0B ¥0B ¥0B ¥0B ¥0B
Net Worth (Common Equity) ¥1B ¥1B ¥2B ¥2B ¥2B
Return on Total Assets (ROA) 3.6% 12.9% 12.5% 9.3% 10.8%
Return on Common Equity (ROE) 5.0% 18.7% 16.6% 12.7% 13.4%
Business Summary & Analysis
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays...
Capital Strategy Targets
No active capital policy disclosure records found.
Tokyo Intelligence Filings System · Company Fact Sheet Generative Extraction Layer (Sonnet/Haiku) · Date: 2026-06-13